Growth Stories With IBD Investor's Business Daily

Since its market debut in 2017, Celsius has been 'bubbling' up explosive growth for investors. But the company's turbocharged performance has set a high bar — leaving investors and Wall Street to wonder if Celsius' fast pace of growth is sustainable. On this Growth Stories Spotlight, Celsius CEO John Fieldly talks about the energy drink market and the growth drivers pushing Celsius forward in the year ahead.

On this Growth Stories Spotlight, Informatica CEO Amit Walia gives us details on how the AI megatrend is boosting cloud computing growth and why being the Switzerland of data is helping the company stand out in the competitive data management landscape.

Since its blockbuster return to the public market in September 2023, chip designer Arm has dazzled investors with its strong price history. And while the company is known for its mobile phone technology, CEO Rene Haas has signaled that Arm’s automotive segment is a key area of focus as the era of smart cars has upped the demand — and price — for the high-performing chips powering our vehicles. 
On this Growth Stories Spotlight, Arm’s head of automotive Dipti Vachani takes us on a deep dive into the chip designer’s strategy and why the company is focused on the auto segment as a pillar of future success.

Adobe was one of the hottest stocks in 2023 thanks to the artificial intelligence tidal wave. But that growth has slowed as the AI feeding frenzy begins to settle. Adobe saw a similar pullback last year before the introduction of Firefly propelled shares higher. And with new AI powered-tools taking center stage at this year’s Adobe Summit, investors will find out if Adobe stock will sing a similar tune — or fall out of rhythm with the market.
On this Growth Stories Spotlight, we speak to Anil Chakravarthy, who heads the digital experience business at Adobe, to get an inside look at the company’s AI strategy and the road ahead.

Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using CRISPR technology to treat sickle cell disease.
Government approval of these groundbreaking treatments could generate an unprecedented wave of medical innovation. But gene editing therapies aren't without risk, and questions remain about the safety and cost effectiveness of these experimental treatments.
On this episode of Growth Stories, we dive into the science of gene editing treatments and how the boom in gene therapy drug approvals could transform the healthcare industry.

Microsoft became a dominant tech powerhouse when Windows PCs and Internet Explorer emerged as critical tools of the web revolution. Now the software giant is trying to regain its leadership role with generative artificial intelligence — and Wall Street is paying close attention. On this episode of Growth Stories, we look at Microsoft’s push into artificial intelligence — and how the tech titan plans to use that technology to fuel a new era of growth.